Literature DB >> 30926125

Lower prevalence of non-cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility.

Hao Huang1, Hongying Kuang2, Fangbai Sun1, Michael P Diamond3, Richard S Legro4, Christos Coutifaris5, Ruben Alvero6, Randal D Robinson7, Peter R Casson8, Gregory M Christman9, Karl R Hansen10, Nanette Santoro6, Esther Eisenberg11, Heping Zhang12.   

Abstract

OBJECTIVE: To study whether there is a difference in the prevalence of non-cavity-distorting uterine fibroids between infertile patients with polycystic ovary syndrome (PCOS) and those with unexplained infertility (UI).
DESIGN: A secondary analysis of data from three randomized clinical trials.
SETTING: Academic health centers. PATIENT(S): A total of 2,249 patients with normal uterine cavities. INTERVENTIONS(S): None. MAIN OUTCOME MEASURE(S): The presence or absence of non-cavity-distorting fibroids. RESULT(S): Compared with women with UI, those with PCOS were younger, had a higher body mass index, and were more likely to be Hispanic or African American, with a lower percentage of previous conception and live birth, a higher percentage of current smokers, a lower percentage of current alcohol users, and higher total testosterone, fasting insulin, and homeostasis-model-assessment insulin resistance. The prevalence of women with non-cavity-distorting uterine fibroids was lower in women with PCOS than in those with UI (6.7% vs. 12.4%); this result held after patients were divided into Black and non-Black or into three different body mass index groups. After adjustment for all the other variables in the final model, patients with PCOS had a significantly lower prevalence of fibroids than those with UI (odds ratio 0.54). No differences in the prevalence of non-cavity-distorting fibroids with any dimensions ≥4 cm or the volume of the largest fibroid was found between the two groups. CONCLUSION(S): A lower prevalence of non-cavity-distorting uterine fibroids was found in infertile women with PCOS than in those with UI.
Copyright © 2019 American Society for Reproductive Medicine. All rights reserved.

Entities:  

Keywords:  PCOS; non–cavity-distorting fibroids; risk factor; unexplained infertility

Mesh:

Year:  2019        PMID: 30926125      PMCID: PMC6487215          DOI: 10.1016/j.fertnstert.2019.01.020

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  41 in total

Review 1.  The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis.

Authors:  Sesh Kamal Sunkara; Mohammed Khairy; Tarek El-Toukhy; Yacoub Khalaf; Arri Coomarasamy
Journal:  Hum Reprod       Date:  2009-11-12       Impact factor: 6.918

2.  Hypertension, obesity, and fibromyomata uteri, as a syndrome.

Authors:  W E Summers; R L Watson; W H Wooldridge; H G Langford
Journal:  Arch Intern Med       Date:  1971-11

3.  Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.

Authors:  A E Taylor; B McCourt; K A Martin; E J Anderson; J M Adams; D Schoenfeld; J E Hall
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

4.  The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial.

Authors:  Richard S Legro; Robert G Brzyski; Michael P Diamond; Christos Coutifaris; William D Schlaff; Ruben Alvero; Peter Casson; Gregory M Christman; Hao Huang; Qingshang Yan; Daniel J Haisenleder; Kurt T Barnhart; G Wright Bates; Rebecca Usadi; Richard Lucidi; Valerie Baker; J C Trussell; Stephen A Krawetz; Peter Snyder; Dana Ohl; Nanette Santoro; Esther Eisenberg; Heping Zhang
Journal:  Fertil Steril       Date:  2013-10-21       Impact factor: 7.329

Review 5.  Uterine fibroids.

Authors:  E A Stewart
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

6.  Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics.

Authors:  Michael P Diamond; Richard S Legro; Christos Coutifaris; Ruben Alvero; Randal D Robinson; Peter Casson; Gregory M Christman; Joel Ager; Hao Huang; Karl R Hansen; Valerie Baker; Rebecca Usadi; Aimee Seungdamrong; G Wright Bates; R Mitchell Rosen; Daniel Haisonleder; Stephen A Krawetz; Kurt Barnhart; J C Trussell; Yufeng Jin; Nanette Santoro; Esther Eisenberg; Heping Zhang
Journal:  Fertil Steril       Date:  2015-02-20       Impact factor: 7.329

7.  Risk factors for clinically diagnosed uterine fibroids in women around menopause.

Authors:  Fabio Parazzini
Journal:  Maturitas       Date:  2006-03-13       Impact factor: 4.342

Review 8.  The gonadotropic function of insulin.

Authors:  L Poretsky; M F Kalin
Journal:  Endocr Rev       Date:  1987-05       Impact factor: 19.871

Review 9.  Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications.

Authors:  Molly B Moravek; Ping Yin; Masanori Ono; John S Coon; Matthew T Dyson; Antonia Navarro; Erica E Marsh; Debabrata Chakravarti; J Julie Kim; Jian-Jun Wei; Serdar E Bulun
Journal:  Hum Reprod Update       Date:  2014-09-08       Impact factor: 15.610

10.  Uterine leiomyomata in relation to insulin-like growth factor-I, insulin, and diabetes.

Authors:  Donna D Baird; Greg Travlos; Ralph Wilson; David B Dunson; Michael C Hill; Aimee A D'Aloisio; Stephanie J London; Joel M Schectman
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

View more
  1 in total

1.  Assessing burden, risk factors, and perceived impact of uterine fibroids on women's lives in rural Haiti: implications for advancing a health equity agenda, a mixed methods study.

Authors:  Christophe Millien; Anatole Manzi; Arlene M Katz; Hannah Gilbert; Mary C Smith Fawzi; Paul E Farmer; Joia Mukherjee
Journal:  Int J Equity Health       Date:  2021-01-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.